Epithalon: The Human Evidence Belongs to a Different Substance

What it is

Epithalon is a synthetic tetrapeptide, four amino acids end to end, Ala-Glu-Asp-Gly, also written Epitalon, molecular weight 390.35, PubChem CID 219042. Vladimir Khavinson is the named inventor on US 6,727,227 B1, granted 27 April 2004 and assigned to the limited liability company of the Clinic of the Institute of Bioregulation and Gerontology.

Now the part that decides everything else on this page. Epitalon was synthesised on the basis of the amino acid composition of Epithalamin, a bovine pineal gland extract, which makes it an analogue of that extract rather than the extract itself. Somebody read the amino acids off a jar of ground cow pineal gland, built four of them into a chain, and the chain inherited the jar's clinical record and a name one letter away. FDA states in a footnote of its briefing document that it considers epitalon and epithalamin different substances, epithalamin being a polypeptide complex extracted from animal pineal gland.

The trial that is not about this compound

Go to PubMed and pull up 14523363, Khavinson and Morozov, the 266 person study cited whenever somebody claims this compound extends human life. Patients were split into four groups by stratification randomisation: placebo, Thymalin, Epithalamin, or both, everything injected intramuscularly at 10 mg daily for 10 days, 100 mg per course, double blind. Both agents are animal tissue extracts, and the words Epitalon, Epithalon and Ala-Glu-Asp-Gly appear nowhere in the paper. (PMID 14523363)

The celebrated 4.1 fold mortality reduction comes out of that same paper: 20 patients given both extracts annually for six years against a control arm of 22. The Epithalamin only arm of 24 had a six year mortality of 45.8 percent against 81.8 percent in control. Real patients, real randomisation, real numbers, different substance.

The Kiev Institute of Gerontology follow up, also cited in epithalon marketing, used epithalamin the extract too. Over three years, 39 coronary patients received regular courses of it on top of basic therapy against 40 controls on basic therapy alone. (PMID 22451889)

What the tetrapeptide itself has been given to people for

FDA's literature search found exactly three studies in which epitalon was given to human beings: two sublingual sprays in night shift workers, one parabulbar injection into the tissue around the eyeball.

Ivko and colleagues 2021 is the only randomised, placebo controlled study of the tetrapeptide in humans. Seventy five healthy women aged 40 to 50 working mainly night shifts were sorted by urinary 6-sulfatoxymelatonin, a melatonin breakdown product. The 35 with age appropriate levels became a non randomised reference group; the 40 with low levels were split into two arms of 20 and given, for 20 days, either a saline sublingual spray or an AEDG spray delivering 0.5 mg a day. 6-sulfatoxymelatonin rose 1.7 fold on the peptide and did not move on placebo. The publication did not specify blinding and measured no sleep outcome.

The 2002 retinitis pigmentosa paper is the only PubMed record for epithalon or epitalon carrying the Clinical Trial publication type, and its entire human result is one sentence: a positive clinical effect in 90 percent of cases, with no patient count, dose, schedule or control group in the abstract. (PMID 12195242) I found no published study giving epitalon to a human by subcutaneous injection, the route the entire community convention runs on.

The telomere work never left the dish

The founding claim is a 2003 cell culture experiment from Khavinson's own group: adding Epithalon to telomerase negative human fetal fibroblasts induced hTERT expression, telomerase activity and telomere elongation. (PMID 12937682) The concentration is absent from the abstract, and I could only recover it from FDA's read of the full paper: 50 nanograms per millilitre for four days in human fetal lung fibroblasts.

Independent replication exists. A group at Brunel University London, declaring no competing interests, reproduced dose dependent telomere lengthening in normal human cells, IBR.3 fibroblasts and HMEC epithelial cells, at 1.0 micrograms per millilitre daily for three weeks. In the breast cancer lines 21NT and BT474, at 0.1 to 1.0 micrograms per millilitre daily for four days, telomeres lengthened too, but through ALT, alternative lengthening of telomeres, which the authors call cancer cell specific. (PMID 40908429) The paper carries a published correction covering figure reproduction only.

I found no study that has measured telomere length or telomerase activity in a human being given epitalon. FDA raises the mechanism as a hazard rather than a selling point: continuous lifelong exposure to something that lengthens telomeres could let cells evade senescence and turn cancerous.

The animals, and a dose that cannot be right

Anisimov 2003 is the best powered lifespan study: 54 female outbred Swiss derived SHR mice per group, injected subcutaneously on five consecutive days every month from three months of age until natural death, 1.0 microgram per mouse, roughly 30 to 40 micrograms per kilogram. Epitalon did not change mean life span, body weight or food consumption. What moved was maximum life span, up 12.3 percent, the last 10 percent of survivors, up 13.3 percent, leukaemia, down 6.0 fold, bone marrow chromosome aberrations, and the loss of estrous function. (PMID 14501183)

The HER-2/neu tumour result that anchors the anti cancer marketing used 1 microgram per mouse, subcutaneously, five consecutive days every month from two months of age, in female FVB/N transgenics. (PMID 12209581) A Bulletin of Experimental Biology and Medicine paper from the same group, on the same mouse model, states the dose as 1 mg subcutaneously five times a week. (PMID 12459848) One thousand times the figure every companion paper prints, and the record does not resolve which one describes what was done. A reader who takes that milligram at face value and scales it by body weight lands three orders of magnitude away from anything ever given an animal.

Where the 10 mg came from

Two protocols circulate, both subcutaneous. The one usually called the Russian protocol is 10 mg per day for 10 consecutive days, 100 mg per course, and the Ukrainian one is 10 mg on days 1, 5, 9, 13 and 17, 50 mg per course, both typically run one to two times a year with 4 to 6 month breaks. peptides.org attributes both to the International Peptide Society. That is convention and marketing practice, not a finding.

Trace them and they land back on the 2003 extract paper. Its St Petersburg arm gave 10 mg intramuscularly daily for 10 days, 100 mg per course, which is the Russian protocol digit for digit, and its Kiev arm gave 10 mg intramuscularly in five consecutive doses, 50 mg per course, which is the Ukrainian one. Both arms used the bovine extract, and the route was intramuscular where the convention injects under the skin. I found no vendor or clinic page that derives the 10 mg figure from any study of the tetrapeptide.

What nobody has measured

I found no pharmacokinetic study of epitalon in any species, so nobody has published how long a dose lasts, whether the intact tetrapeptide survives sublingual or subcutaneous delivery, or what fraction reaches any tissue. FDA identified no repeat dose toxicity study and no two year carcinogenicity study in any form, noted that the monthly schedule in the Anisimov work exposed those mice for about 5.5 months at most, and concluded there are no clinical data supporting human safety, singling out the subcutaneous route for immunogenicity risk from aggregation and impurities.

I could not find this compound on ClinicalTrials.gov, by term or intervention. No approved epitalon product exists in any market FDA checked, and no European Medicines Agency authorisation.

The indication FDA formally evaluated was insomnia, and it found no publication on efficacy in insomnia patients and no study using the proposed subcutaneous route. My own search found none either.

My read

Khavinson and Morozov were straight about what they gave people. The agents are named, the milligrams are printed, the randomisation is described, and the tetrapeptide is not in it. What went wrong went wrong downstream, where a name shifted by one letter and the mortality table came with it. Take that away and what is left is 20 women on a sublingual spray, a one sentence eye result with no patient count, telomere lengthening in dishes, and a mouse study where mean life span did not move across 54 animals a group.

The cell work is the part I would not dismiss. Brunel had no stake in the result and got it anyway. But that same lab watched the peptide drive ALT in two breast cancer lines, FDA reads the whole telomerase story as a cancer concern, and FDA found no two year carcinogenicity study to settle it. I have not found a single telomere measurement in a person who took this.

If you have bought epithalon, what did the seller cite for the 10 mg figure? I would like to see one page that names a study of the tetrapeptide.

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.